Patientenmonitoring 4.0

Autor: Michael Bauer, B. C. Kieseier

Publikováno v: Der Nervenarzt. 90:1205-1206

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3875d51ad5cb5fac791361390327534e
https://doi.org/10.1007/s00115-019-00823-w

A 10-year follow-up of the European multicenter trial of interferon beta-1b in secondary-progressive multiple sclerosis

Autor: Antonios Bayas, Kp Wandinger, Sten Fredrikson, Cyrille B. Confavreux, B. C. Kieseier, Ludwig Kappos, Mathias Buttmann, Jordi Río, J. De Keyser, David Brassat, Jens Kuhle, Giulio Disanto, Chris H. Polman, M Ecsedi, M. Frontoni, M Hardmeier, Michael Hutchinson, Markus Färkkilä, M. P. Amato, K Baum, T. Kümpfel, Claude Stolz, K Gugleta, M D’hooghe, E Roullet, Bruno Brochet, Karl Vass, Carmen Lienert, Gilles Edan

Publikováno v: Kuhle, J, Hardmeier, M, Disanto, G, Gugleta, K, Ecsedi, M, Lienert, C, Amato, M P, Baum, K, Buttmann, M, Bayas, A, Brassat, D, Brochet, B, Confavreux, C, Edan, G, Färkkilä, M, Fredrikson, S, Frontoni, M, D'Hooghe, M, Hutchinson, M, De Keyser, J, Kieseier, B C, Kümpfel, T, Rio, J, Polman, C, Roullet, E, Stolz, C, Vass, K, Wandinger, K P & Kappos, L 2016, ' A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis ', Multiple Sclerosis, vol. 22, no. 4, pp. 533-543 . https://doi.org/10.1177/1352458515594440
Multiple Sclerosis Journal
Multiple Sclerosis Journal, 2015, 22 (4), pp.533-43. ⟨10.1177/1352458515594440⟩
Multiple sclerosis (Houndmills Basingstoke England)
Multiple sclerosis journal, 22(4), 533-543. SAGE Publications Inc.
Multiple Sclerosis Journal, SAGE Publications, 2015, 22 (4), pp.533-43. ⟨10.1177/1352458515594440⟩
Multiple Sclerosis, 22(4), 533-543. SAGE Publications Ltd

Objectives: To explore long-term effects of treatment and prognostic relevance of variables assessed at baseline and during the European secondary progressive multiple sclerosis (SPMS) trial of interferon beta 1b (IFNB-1b). Methods: We assessed 362 p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63fb9a32cb72691d91e7b2892c77b3f0
https://doi.org/10.1177/1352458515594440

Aktuelles zur Therapieumstellung bei Multipler Sklerose

Autor: Reinhard Hohlfeld, P. Flachenecker, Thomas Korn, Frauke Zipp, Hayrettin Tumani, Brigitte Wildemann, U. Meier, Felix Luessi, Volker Limmroth, B. C. Kieseier, Wolfgang Brück, H.-P. Hartung, Heinz Wiendl, T. Kümpfel, C. Trebst, Aiden Haghikia, B. Tackenberg, Vinzenz Fleischer, Pierre Kolber, M. Lang, Luisa Klotz, Sven G. Meuth, Martin Stangel, Ralf Gold, B. Hemmer

Publikováno v: Der Nervenarzt. 86:1236-1247

In recent years the approval of new substances has led to a substantial increase in the number of course-modifying immunotherapies available for multiple sclerosis. Therapy conversion therefore represents an increasing challenge. The treatment option

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::20b0054cbd7bce21bf31681d577716f0
https://doi.org/10.1007/s00115-015-4368-8

Bacteria and their cell wall components uniformly co-activate interleukin-17-producing thymocytes

Autor: Andreas P.M. Weber, H.-P. Hartung, Corinna Zimmermann, B. C. Kieseier, Harald H. Hofstetter

Publikováno v: Clinical and Experimental Immunology. 178:504-515

Summary Interleukin (IL)-17-producing T cells play a critical role in the immune response against microbial pathogens. Traditionally, experimental studies have focused upon understanding the activity of IL-17-producing T cells which differentiate fro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ff36ef2e71138ad1159090d7c2ded6d
https://doi.org/10.1111/cei.12414

Dimethylfumarat in der Therapie der schubförmigen MS

Autor: Mathias Mäurer, U. Meier, K. Baum, B. C. Kieseier, H. Wiendl, Thomas Korn, L. Harms, A. Chan, T. Ziemssen, H. Schreiber, B. Tackenberg, H. P. Hartung, H. J. Boldt, Ralf Gold

Publikováno v: Nervenheilkunde. 33:175-179

ZusammenfassungFür die verlaufsmodifizierende Basistherapie der schubförmigen Multiplen Sklerose standen bis vor Kurzem ausschließlich injizierbare Präparate zur Verfügung. Mit Dimethylfumarat (DMF, Tecfidera®) wurde erstmals ein orales Medikam

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::91bcb6daca1a471d52b5f7b1a31d8754
https://doi.org/10.1055/s-0038-1627678